Intelligence · Clinical Pipeline
Théa Pharma Ireland Pipeline
All ClinicalTrials.gov programs at Théa Pharma Ireland — phase, modality, and trial IDs.
- Programs
- 2
Quick answer
Théa Pharma Ireland has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE
Verona Pharma Ireland Limited
Gastric adenocarcinoma with peritoneal metastases
1 trial -
Safinamide 100 mg PLACEBO: Safinamide 100 mg PLACEBO film-coated tablets have the same composition as the relevant Investigational Medicinal Products except for the presence of Active Substance that is missing in the placebo formulations. The missing amount of active substance Safinamide methanesulfonate is replaced in the PLACEBO formulation with the same amount of Microcrystalline cellulose, one of the excipients already present in the authorised formulation, Xadago 100 mg film-coated tablets, Xadago 50 m
Verona Pharma Ireland Limited
PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS
1 trial
Frequently asked questions
How many pipeline programs does Théa Pharma Ireland have?
2 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs